https://www.pharmaradar360.com/article/phlow-appoints-sripathy-venkatraman-as-chief-scientific-officer-69e793efcdfbb43cPharma Surgeen2026-07-22T16:19:24.000ZPhlow Appoints Sripathy Venkatraman as Chief Scientific Officerhttps://www.pharmaradar360.com/article/revvity-to-launch-signals-for-startups-for-emerging-biotech-companies-4c13f314ab8a7c22Pharma Surgeen2026-07-22T16:18:55.000ZRevvity to Launch Signals for Startups for Emerging Biotech Companieshttps://www.pharmaradar360.com/article/once-daily-therapy-eases-early-parkinson-s-symptoms-in-phase-3-trial-988460739e6f7146Pharma Surgeen2026-07-22T16:18:45.000ZOnce-daily therapy eases early Parkinson’s symptoms in Phase 3 trialhttps://www.pharmaradar360.com/article/what-to-watch-forthcoming-limitation-on-dtc-pharmaceutical-ads-1e6814a45a3acc6ePharma Surgeen2026-07-22T15:40:17.000ZWhat to Watch: Forthcoming Limitation on DTC Pharmaceutical Adshttps://www.pharmaradar360.com/article/fda-strives-for-balance-amid-political-turbulence-and-staffing-rebuild-a1d2966b5ac2f407Pharma Surgeen2026-07-22T15:32:23.000ZFDA Strives for Balance Amid Political Turbulence and Staffing Rebuildhttps://www.pharmaradar360.com/article/biotech-experts-want-fda-drug-reviews-based-on-science-not-politics-1b5b962723a2efd2Pharma Surgeen2026-07-22T15:32:15.000ZBiotech experts want FDA drug reviews based on science, not politicshttps://www.pharmaradar360.com/article/biotech-experts-want-fda-drug-reviews-based-on-science-not-politics-244dd2c6a3a63276Pharma Surgeen2026-07-22T15:31:40.000ZBiotech experts want FDA drug reviews based on science, not politicshttps://www.pharmaradar360.com/article/ns-025-286b33c918c47f2cPharma Surgeen2026-07-22T15:30:00.000ZNS-025の全世界における開発・製造・販売に関する独占的ライセンス契約締結のお知らせhttps://www.pharmaradar360.com/article/nhs-bursary-scheme-rules-71af26dfb41e572bPharma Surgeen2026-07-22T15:09:10.000ZNHS Bursary Scheme ruleshttps://www.pharmaradar360.com/article/nhs-bursary-scheme-rules-2026-to-2027-b54d3b5d61fb4d10Pharma Surgeen2026-07-22T15:09:04.000ZNHS Bursary Scheme rules 2026 to 2027https://www.pharmaradar360.com/article/pharmaceutical-drug-costs-are-a-workers-rights-issue-8bf36e3c6433ab66Pharma Surgeen2026-07-22T15:04:31.000ZPharmaceutical drug costs are a workers’ rights issuehttps://www.pharmaradar360.com/article/allergy-medication-recall-warns-of-life-threatening-reaction-cbe37227fd5e3912Pharma Surgeen2026-07-22T14:55:59.000ZAllergy medication recall warns of life-threatening reactionhttps://www.pharmaradar360.com/article/pharma-tries-to-tamp-down-broad-china-restrictions-b1d68e0e74d055ecPharma Surgeen2026-07-22T14:23:14.000ZPharma tries to tamp down broad China restrictionshttps://www.pharmaradar360.com/article/mentari-adds-200m-to-migraine-mission-royalty-s-latest-attr-cm-deal-17eb3083d088bf29Pharma Surgeen2026-07-22T14:17:00.000ZMentari adds $200M to migraine mission; Royalty’s latest ATTR-CM dealhttps://www.pharmaradar360.com/article/samsung-biologics-geographic-diversification-is-a-sound-business-decision-4681452cd7fee15bPharma Surgeen2026-07-22T14:15:07.000ZSamsung Biologics: geographic diversification is a sound business decisionhttps://www.pharmaradar360.com/article/biotech-s-takeover-boom-may-be-running-out-of-buyers-126c96619f7f7a15Pharma Surgeen2026-07-22T14:03:00.000ZBiotech's takeover boom may be running out of buyershttps://www.pharmaradar360.com/article/pharma-horizons-nitrosamines-284c5da38295c58fPharma Surgeen2026-07-22T13:51:57.000ZPharma Horizons: Nitrosamineshttps://www.pharmaradar360.com/article/rapid-microbiology-in-history-a-timeline-to-usp-7c1084589b70de83Pharma Surgeen2026-07-22T13:51:56.000ZRapid microbiology in history: a timeline to USPhttps://www.pharmaradar360.com/article/the-biotech-bi-weekly-multiomics-human-cell-based-research-next-gen-cell-recover-25380264aadd349dPharma Surgeen2026-07-22T13:31:20.000ZThe biotech bi-weekly: multiomics, human cell-based research, next-gen cell recovery and biomarker developmenthttps://www.pharmaradar360.com/article/redwire-opens-research-and-microgravity-payload-development-facility-edeb77f066b28a33Pharma Surgeen2026-07-22T13:29:25.000ZRedwire opens research and microgravity payload development facilityhttps://www.pharmaradar360.com/article/mid-year-check-in-has-prior-auth-reform-delivered-94ad4aeaa19277bdPharma Surgeen2026-07-22T13:22:36.000ZMid-Year Check-In: Has Prior Auth Reform Delivered?https://www.pharmaradar360.com/article/here-s-why-you-should-add-savara-stock-to-your-portfolio-now-827ab5c502976c29Pharma Surgeen2026-07-22T13:21:00.000ZHere's Why You Should Add Savara Stock to Your Portfolio Nowhttps://www.pharmaradar360.com/article/trump-s-generic-drug-tariffs-what-they-could-mean-for-medicine-prices-manufactur-5e126f9e50f0c9c4Pharma Surgeen2026-07-22T13:14:25.000ZTrump's generic drug tariffs: What they could mean for medicine prices, manufacturers and supplyhttps://www.pharmaradar360.com/article/biotech-pre-market-pulse-labt-inm-pmi-drives-early-market-momentum-3ff11a3120b2bd4bPharma Surgeen2026-07-22T13:12:00.000ZBiotech Pre-Market Pulse: LABT, INM, PMI Drives Early Market Momentumhttps://www.pharmaradar360.com/article/trinity-biotech-trib-announces-reverse-ads-split-to-meet-nasda-b939aa7f6217d1ebPharma Surgeen2026-07-22T13:11:22.000ZTrinity Biotech (TRIB) Announces Reverse ADS Split to Meet Nasdahttps://www.pharmaradar360.com/article/evercore-isi-initiates-tenax-therapeutics-stock-coverage-with-outperform-rating-38a51af37c79019cPharma Surgeen2026-07-22T13:02:00.000ZEvercore ISI initiates Tenax Therapeutics stock coverage with outperform ratinghttps://www.pharmaradar360.com/article/what-would-200-us-tariffs-on-generic-drugs-mean-for-china-s-pharmaceutical-indus-2a2c44b158e3fe7ePharma Surgeen2026-07-22T13:00:15.000ZWhat would 200% US tariffs on generic drugs mean for China’s pharmaceutical industry?https://www.pharmaradar360.com/article/biotech-industry-leaders-file-brief-backing-fda-against-malicious-mifepristone-c-6beaffd3b6ca5978Pharma Surgeen2026-07-22T13:00:00.000ZBiotech industry leaders file brief backing FDA against ‘malicious’ mifepristone challengehttps://www.pharmaradar360.com/article/single-use-support-speeds-design-cycle-for-pharma-f94b56369272d118Pharma Surgeen2026-07-22T12:58:24.000ZSingle Use Support speeds design cycle for pharmahttps://www.pharmaradar360.com/article/price-to-book-forward-of-jiangxi-synergy-pharmaceutical-co-ltd-class-a-szse-3006-3347032e96df13fcPharma Surgeen2026-07-22T12:55:35.000ZPrice to book forward of Jiangxi Synergy Pharmaceutical Co. Ltd. Class A – SZSE:300636https://www.pharmaradar360.com/article/trinity-biotech-trib-adjusts-ads-ratio-to-meet-compliance-requ-b378e8d8f3791dbePharma Surgeen2026-07-22T12:53:19.000ZTrinity Biotech (TRIB) Adjusts ADS Ratio to Meet Compliance Requhttps://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-jiangsu-lianhuan-pharmaceutical-co-ltd-cl-05eb1ff213c70ea6Pharma Surgeen2026-07-22T12:46:36.000ZEnterprise value to revenue forward of Jiangsu Lianhuan Pharmaceutical Co., Ltd. Class A – SSE:600513https://www.pharmaradar360.com/article/ad-hoc-marinomed-biotech-ag-files-for-court-restructuring-proceedings-without-se-e246325b9cbeae52Pharma Surgeen2026-07-22T12:43:54.000ZAd-hoc: Marinomed Biotech AG files for court restructuring proceedings without self-administrationhttps://www.pharmaradar360.com/article/fda-opens-door-for-uganda-s-cancer-drug-9b26b81f427654f6Pharma Surgeen2026-07-22T12:38:35.000ZFDA opens door for Uganda’s cancer drughttps://www.pharmaradar360.com/article/trinity-biotech-partners-with-latch-medical-on-metabolic-health-tech-11643fd5e2c1fc05Pharma Surgeen2026-07-22T12:33:15.000ZTrinity Biotech partners with Latch Medical on metabolic health techhttps://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-vytrus-biotech-sa-tradegate-v5p-643551311280f841Pharma Surgeen2026-07-22T12:26:54.000ZEnterprise value to EBITDA forward of Vytrus Biotech SA – TRADEGATE:V5Phttps://www.pharmaradar360.com/article/trinity-biotech-plans-1-for-30-reverse-ads-split-c34e78df90e3a142Pharma Surgeen2026-07-22T12:11:06.000ZTrinity Biotech plans 1-for-30 reverse ADS splithttps://www.pharmaradar360.com/article/lb-pharmaceuticals-announces-accelerated-timing-of-topline-results-from-the-phas-14b95bfd2fa32731Pharma Surgeen2026-07-22T12:10:44.000ZLB Pharmaceuticals Announces Accelerated Timing of Topline Results from the Phase 3 NOVA-2 Trial of LB-102 in Schizophreniahttps://www.pharmaradar360.com/article/trinity-biotech-nasdaq-trib-plans-equity-backed-latch-medical-tie-up-in-cgm-guid-36c636c22c65257cPharma Surgeen2026-07-22T12:02:40.000ZTrinity Biotech (NASDAQ: TRIB) plans equity-backed Latch Medical tie-up in CGM-guided drug deliveryhttps://www.pharmaradar360.com/article/trinity-biotech-nasdaq-trib-sets-1-for-30-reverse-ads-split-70e5581bc001b6f4Pharma Surgeen2026-07-22T12:00:37.000ZTrinity Biotech (Nasdaq: TRIB) sets 1-for-30 reverse ADS splithttps://www.pharmaradar360.com/article/fda-accepts-bridgebio-s-nda-for-encaleret-to-tr-3cd2d0990bd3529cPharma Surgeen2026-07-22T12:00:02.000ZFDA accepts BridgeBio's NDA for encaleret to tr...https://www.pharmaradar360.com/article/dca-vantage-hba1c-dx-claim-88bbe7e49ec03389Pharma Surgeen2026-07-22T12:00:00.000ZDCA Vantage® HbA1c (DX Claim)https://www.pharmaradar360.com/article/lb-pharmaceuticals-expects-results-from-460-patient-trial-in-1h-2027-28ca1d17e429797bPharma Surgeen2026-07-22T12:00:00.000ZLB Pharmaceuticals Expects Results From 460-Patient Trial in 1H 2027https://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-biotech-growth-trust-plc-turquoise-biogl-af3e80e1ab588b99Pharma Surgeen2026-07-22T11:46:58.000ZEnterprise value to EBITDA forward of Biotech Growth Trust PLC – TURQUOISE:BIOGLhttps://www.pharmaradar360.com/article/mhra-approves-first-hfa-152a-propellant-pmdi-inhalers-8a4e48e4dc3f6777Pharma Surgeen2026-07-22T11:33:01.000ZMHRA approves first HFA-152a propellant pMDI inhalershttps://www.pharmaradar360.com/article/new-autologous-t-cell-therapy-offers-hope-for-children-with-brain-tumors-52e0d33b2719579dPharma Surgeen2026-07-22T11:32:58.000ZNew autologous T cell therapy offers hope for children with brain tumorshttps://www.pharmaradar360.com/article/rep-buchanan-celebrates-passing-of-bill-cracking-down-on-animal-testing-758cf4a7834b9ac7Pharma Surgeen2026-07-22T11:31:13.000ZRep. Buchanan Celebrates Passing Of Bill Cracking Down On Animal Testinghttps://www.pharmaradar360.com/article/trinity-biotech-s-wearable-sensors-may-guide-drug-delivery-0b66a6a4564c8bb9Pharma Surgeen2026-07-22T11:30:00.000ZTrinity Biotech's Wearable Sensors May Guide Drug Deliveryhttps://www.pharmaradar360.com/article/reunion-del-comite-de-medicamentos-de-uso-humano-de-junio-de-2026-fe98ddbadc0431bfPharma Surgeen2026-07-22T11:26:46.000ZReunión del Comité de Medicamentos de Uso Humano de junio de 2026https://www.pharmaradar360.com/article/west-pharmaceutical-services-wst-q2-earnings-report-preview-what-to-look-for-b524a39e152897b5Pharma Surgeen2026-07-22T11:23:35.000ZWest Pharmaceutical Services (WST) Q2 Earnings Report Preview: What To Look Forhttps://www.pharmaradar360.com/article/trinity-biotech-announces-1-for-30-reverse-ads-split-to-regain-nasdaq-compliance-bdaaf93e13689751Pharma Surgeen2026-07-22T11:20:00.000ZTrinity Biotech Announces 1-for-30 Reverse ADS Split to Regain Nasdaq Compliancehttps://www.pharmaradar360.com/article/west-pharmaceutical-services-wst-q2-earnings-report-preview-what-to-look-for-74dfd2b5d2487501Pharma Surgeen2026-07-22T11:19:00.000ZWest Pharmaceutical Services (WST) Q2 Earnings Report Preview: What To Look Forhttps://www.pharmaradar360.com/article/what-leadership-looks-like-the-future-of-esg-in-healthcare-and-biotech-9f6b186470c5f4afPharma Surgeen2026-07-22T11:16:55.000ZWhat Leadership Looks Like: The Future of ESG in Healthcare and Biotechhttps://www.pharmaradar360.com/article/price-to-sales-forward-of-biotech-growth-trust-plc-turquoise-biogl-eef6524aa81239b1Pharma Surgeen2026-07-22T11:16:04.000ZPrice to sales forward of Biotech Growth Trust PLC – TURQUOISE:BIOGLhttps://www.pharmaradar360.com/article/trinity-biotech-plc-announces-plan-to-implement-ads-ratio-change-0b05c44fd3e47cf2Pharma Surgeen2026-07-22T11:15:10.000ZTrinity Biotech Plc Announces Plan to Implement ADS Ratio Changehttps://www.pharmaradar360.com/article/trinity-biotech-plans-mandatory-exchange-of-30-adss-for-1-on-july-24-16e054168fa7ea96Pharma Surgeen2026-07-22T11:15:00.000ZTrinity Biotech Plans Mandatory Exchange of 30 ADSs for 1 on July 24https://www.pharmaradar360.com/article/la-aemps-informa-de-la-retirada-de-equipos-para-cicladora-personal-homechoice-co-84e44065e068ed57Pharma Surgeen2026-07-22T11:07:30.000ZLa AEMPS informa de la retirada de equipos para Cicladora Personal HomeChoice con cassette y 4 líneashttps://www.pharmaradar360.com/article/in-vitro-74ac217207dda3c4Pharma Surgeen2026-07-22T11:03:57.000ZΣχετικά με την προσφορά οικονομικών παροχών σε συμμετέχοντες σε κλινικές δοκιμές με φάρμακα, κλινικές έρευνες με ιατροτεχνολογικά προϊόντα και μελέτες επιδόσεων με in vitro διαγνωστικά προϊόνταhttps://www.pharmaradar360.com/article/tilorone-dihydrochloride-market-growth-forecast-to-2035-pharmaceutical-r-d-and-i-3b7b927954af9822Pharma Surgeen2026-07-22T11:01:13.000ZTilorone Dihydrochloride Market Growth Forecast to 2035: Pharmaceutical R&D and Industrial Applications Drive Expansion - News and Statisticshttps://www.pharmaradar360.com/article/rethinking-cardiovascular-risk-and-e-bike-safety-in-the-modern-age-4472ae01a2228edcPharma Surgeen2026-07-22T11:00:42.000ZRethinking Cardiovascular Risk and E-Bike Safety in the Modern Agehttps://www.pharmaradar360.com/article/annual-epidemiological-commentary-gram-negative-mrsa-mssa-bacteraemia-and-c-diff-eb098c2f1b06a9a0Pharma Surgeen2026-07-22T11:00:06.000ZAnnual epidemiological commentary: Gram-negative, MRSA, MSSA bacteraemia and C. difficile infections, up to and including financial year 2025 to 2026https://www.pharmaradar360.com/article/tiziana-life-sciences-announces-purchase-of-shares-by-executive-chairman-77d1117229596041Pharma Surgeen2026-07-22T11:00:00.000ZTiziana Life Sciences Announces Purchase of Shares by Executive Chairmanhttps://www.pharmaradar360.com/article/ftse4good-index-series-3-f60590ce87bfbfa9Pharma Surgeen2026-07-22T11:00:00.000ZFTSE4Good Index Seriesの構成銘柄に3年連続で選定https://www.pharmaradar360.com/article/okyo-pharma-plans-phase-3-trial-for-single-dose-eye-pain-drug-e91f89f515d51611Pharma Surgeen2026-07-22T11:00:00.000ZOKYO Pharma Plans Phase 3 Trial for Single-Dose Eye Pain Drughttps://www.pharmaradar360.com/article/the-biotech-recovery-gathers-speed-in-q2-b4890d4f77cbc05cPharma Surgeen2026-07-22T10:45:00.000ZThe biotech recovery gathers speed in Q2https://www.pharmaradar360.com/article/acetonitrile-market-to-reach-usd-567-5-million-by-2035-as-pharmaceutical-manufac-ed0557192a970391Pharma Surgeen2026-07-22T10:38:00.000ZAcetonitrile Market to Reach USD 567.5 Million by 2035 as Pharmaceutical Manufacturing and Lithium-Ion Battery Demand Accelerate Global Growthhttps://www.pharmaradar360.com/article/acetonitrile-market-to-reach-usd-567-5-million-by-2035-as-pharmaceutical-manufac-35b6cb73052cbd2bPharma Surgeen2026-07-22T10:37:00.000ZAcetonitrile Market to Reach USD 567.5 Million by 2035 as Pharmaceutical Manufacturing and Lithium-Ion Battery Demand Accelerate Global Growthhttps://www.pharmaradar360.com/article/biotech-industry-backs-fda-hiring-push-seeks-science-led-drug-reviews-3022b0aa8386c92fPharma Surgeen2026-07-22T10:34:26.000ZBiotech industry backs FDA hiring push, seeks science-led drug reviewshttps://www.pharmaradar360.com/article/former-pharmaceutical-leader-hank-mckinnell-lends-expertise-to-teton-county-sher-889b09ba0d78fcddPharma Surgeen2026-07-22T10:30:00.000ZFormer pharmaceutical leader Hank McKinnell lends expertise to Teton County Sheriff's Officehttps://www.pharmaradar360.com/article/2026-2853b437266b5866Pharma Surgeen2026-07-22T10:24:26.000ZΕκτέλεση προϋπολογισμού ΕΟΦ μηνός Ιουνίου 2026https://www.pharmaradar360.com/article/api-innovation-center-develops-national-fragility-index-to-diversify-pharmaceuti-7d1a53f0a97f0a57Pharma Surgeen2026-07-22T10:18:44.000ZAPI Innovation Center Develops National Fragility Index to Diversify Pharmaceutical Supply Chainshttps://www.pharmaradar360.com/article/2500143f-bentalya-vial-5-25-mg-10ml-9455c0b9112f719cPharma Surgeen2026-07-22T10:18:26.000ZΑνάκληση της παρτίδας 2500143F, του φαρμακευτικού προϊόντος BENTALYA VIAL 5×25 MG/10MLhttps://www.pharmaradar360.com/article/mdd-class-iib-overstritch-suture-cinch-and-sature-cinch-long-90b83cbaff3689fbPharma Surgeen2026-07-22T10:14:31.000ZΑνάκληση των παρτίδων του παρακάτω πίνακα του Ιατροτεχνολογικού προϊόντος κατηγορίας MDD Class IIb, OverStritch Suture Cinch and Sature Cinch-Long, (Εξάρτημα ασφάλισης ράμματος και εξάρτημα ασφάλισης ράμματος μεγάλου μήκους)https://www.pharmaradar360.com/article/hepatitis-b-bepirovirsen-helps-1-in-5-achieve-functional-cure-34cdc10a7a893f26Pharma Surgeen2026-07-22T10:07:27.000ZHepatitis B: Bepirovirsen helps 1 in 5 achieve functional curehttps://www.pharmaradar360.com/article/biotech-experts-want-fda-drug-reviews-based-on-science-not-politics-1af86d5109d9d687Pharma Surgeen2026-07-22T10:00:00.000ZBiotech experts want FDA drug reviews based on science, not politicshttps://www.pharmaradar360.com/article/la-aemps-y-plena-inclusion-madrid-lanzan-una-guia-en-lectura-facil-para-promover-aa8555377b3bfa94Pharma Surgeen2026-07-22T09:54:33.000ZLa AEMPS y Plena Inclusión Madrid lanzan una guía en lectura fácil para promover una exposición solar segurahttps://www.pharmaradar360.com/article/rhode-island-fugitive-convicted-of-rape-captured-after-decades-as-l-a-biotech-ex-c8807e5dad8e7d55Pharma Surgeen2026-07-22T09:43:39.000ZRhode Island fugitive convicted of rape captured after decades as L.A. biotech executivehttps://www.pharmaradar360.com/article/fugitive-doctor-on-run-for-21-years-was-living-as-an-l-a-biotech-executive-950d8d6ded0f3d61Pharma Surgeen2026-07-22T09:40:33.000ZFugitive doctor on run for 21 years was living as an L.A. biotech executivehttps://www.pharmaradar360.com/article/samsung-bioepis-partners-with-prazer-therapeutics-bionsight-on-open-innovation-5a7878aab0b161a7Pharma Surgeen2026-07-22T09:25:19.000ZSamsung Bioepis partners with Prazer Therapeutics, Bionsight on open innovationhttps://www.pharmaradar360.com/article/growth-and-skills-levy-a-catalyst-for-the-uk-pharmaceutical-industry-f480d098599079a2Pharma Surgeen2026-07-22T09:21:11.000ZGrowth and skills levy: A catalyst for the UK pharmaceutical industry?https://www.pharmaradar360.com/article/corporate-report-mhra-policy-for-handling-corporate-conflicts-of-interest-f11ef4de23117133Pharma Surgeen2026-07-22T09:15:59.000ZCorporate report: MHRA: policy for handling corporate conflicts of interesthttps://www.pharmaradar360.com/article/biotech-s-takeover-boom-may-be-running-out-of-buyers-73838381dcf805e0Pharma Surgeen2026-07-22T09:14:00.000ZBiotech's takeover boom may be running out of buyershttps://www.pharmaradar360.com/article/automatic-tablet-counting-system-market-forecast-points-higher-toward-2035-drive-5299a61c8fbb8e7aPharma Surgeen2026-07-22T09:11:13.000ZAutomatic Tablet Counting System Market Forecast Points Higher Toward 2035, Driven by Pharmaceutical Serialization Mandateshttps://www.pharmaradar360.com/article/pharmaceutical-technology-e9121f77fe2ee605Pharma Surgeen2026-07-22T09:10:22.000ZPharmaceutical Technologyhttps://www.pharmaradar360.com/article/hsbc-holdings-plc-has-28-79-million-holdings-in-teva-pharmaceutical-industries-l-cb66a9170c57d3c0Pharma Surgeen2026-07-22T09:01:52.000ZHsbc Holdings PLC Has $28.79 Million Holdings in Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/peptides-get-their-regulatory-close-up-8cf1ae39af56d3c6Pharma Surgeen2026-07-22T09:00:00.000ZPeptides get their regulatory close-uphttps://www.pharmaradar360.com/article/la-ce-publica-unas-recomendaciones-para-identificar-cuando-esta-justificada-la-p-eddd2e7b5aa24ca9Pharma Surgeen2026-07-22T08:47:25.000ZLa CE publica unas recomendaciones para identificar cuándo está justificada la prescripción en cascada de medicamentos veterinarioshttps://www.pharmaradar360.com/article/teva-pharmaceutical-industries-teva-projected-to-post-earnings-on-wednesday-50f24f00b3914edbPharma Surgeen2026-07-22T08:46:27.000ZTeva Pharmaceutical Industries (TEVA) Projected to Post Earnings on Wednesdayhttps://www.pharmaradar360.com/article/0349209e7d5f9e4cPharma Surgeen2026-07-22T08:43:43.000ZΕπίσημη επίσκεψη της Διοίκησης του Εθνικού Οργανισμού Φαρμάκων (ΕΟΦ) στην Κυπριακή Δημοκρατία για την ενίσχυση της συνεργασίας στον τομέα του ρυθμιστικού πλαισίου των φαρμάκωνhttps://www.pharmaradar360.com/article/77-800-shares-in-teva-pharmaceutical-industries-ltd-teva-acquired-by-barometer-c-7a89ad11278c2ae3Pharma Surgeen2026-07-22T08:42:26.000Z77,800 Shares in Teva Pharmaceutical Industries Ltd. $TEVA Acquired by Barometer Capital Management Inc.https://www.pharmaradar360.com/article/boletin-sobre-seguridad-de-medicamentos-de-uso-humano-mayo-de-2026-83443e2df3d0b479Pharma Surgeen2026-07-22T08:01:09.000ZBoletín sobre Seguridad de Medicamentos de Uso Humano. Mayo de 2026https://www.pharmaradar360.com/article/biotech-company-files-bankruptcy-petition-against-smolt-producer-d08327e6ddca2fc3Pharma Surgeen2026-07-22T07:57:45.000ZBiotech company files bankruptcy petition against smolt producerhttps://www.pharmaradar360.com/article/biotech-hair-growth-brand-re-you-launches-2edb8f54a86fffd8Pharma Surgeen2026-07-22T07:25:20.000ZBiotech Hair Growth Brand Re:You Launcheshttps://www.pharmaradar360.com/article/first-aid-a-short-week-biotech-rolls-on-c21eb91bf09a2d68Pharma Surgeen2026-07-22T07:18:36.000ZFIRST AID: A short week, biotech rolls onhttps://www.pharmaradar360.com/article/wegovy-seeks-korea-approval-to-treat-mash-expanding-beyond-obesity-chosunbiz-d200afd0168a6dc9Pharma Surgeen2026-07-22T07:13:00.000ZWegovy seeks Korea approval to treat MASH, expanding beyond obesity - CHOSUNBIZhttps://www.pharmaradar360.com/article/singapore-based-biotech-startup-tikva-allocell-closes-8-m-series-a-funding-round-70dc9bec44812481Pharma Surgeen2026-07-22T07:12:27.000ZSingapore-based biotech startup Tikva Allocell closes $8 M Series A funding roundhttps://www.pharmaradar360.com/article/royalty-pharma-acquires-royalty-interest-in-astrazeneca-s-cliramitug-for-up-to-4-0da27cf035ebe7b9Pharma Surgeen2026-07-22T11:07:08.000ZRoyalty Pharma acquires royalty interest in AstraZeneca’s cliramitug for up to $425 million from Neurimmunehttps://www.pharmaradar360.com/article/solvent-dehydration-chemicals-market-to-reach-usd-2-078-2-million-by-2036-as-pha-697c8ef62e53f5c8Pharma Surgeen2026-07-22T07:04:06.000ZSolvent Dehydration Chemicals Market to Reach USD 2,078.2 Million by 2036 as Pharmaceutical Manufacturing and High-Purity Solvent Recovery Accelerate Global Demandhttps://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-hanmi-pharmaceutical-co-ltd-krx-128940-22853b0802c8b997Pharma Surgeen2026-07-22T06:54:52.000ZEnterprise value to EBITDA forward of Hanmi Pharmaceutical Co., Ltd. – KRX:128940https://www.pharmaradar360.com/article/armata-submits-phase-3-protocol-for-ap-sa02-bacteriophage-in-s-aureus-bacteremia-e0013c0168187e8dPharma Surgeen2026-07-22T06:54:11.000ZArmata Submits Phase 3 Protocol for AP-SA02 Bacteriophage in S. aureus Bacteremiahttps://www.pharmaradar360.com/article/major-new-pharmaceutical-policy-us-tariffs-on-generic-drugs-to-double-progressiv-a87ccc409cf9b602Pharma Surgeen2026-07-22T06:24:19.000ZMajor new pharmaceutical policy! US tariffs on generic drugs to double progressively, up to 200%https://www.pharmaradar360.com/article/fugitive-doctor-on-run-for-21-years-was-living-as-l-a-biotech-exec-4f2e50e4d0c9f39fPharma Surgeen2026-07-22T06:11:33.000ZFugitive doctor on run for 21 years was living as L.A. biotech exechttps://www.pharmaradar360.com/article/why-is-sun-pharmaceutical-industries-stock-falling-today-dc875cc497ed52a8Pharma Surgeen2026-07-22T06:11:15.000ZWhy is Sun Pharmaceutical Industries stock falling today?https://www.pharmaradar360.com/article/fda-warns-of-recalled-allergy-drug-over-contamination-risk-89737f8b1a3e0b43Pharma Surgeen2026-07-22T05:48:41.000ZFDA Warns of Recalled Allergy Drug Over Contamination Riskhttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-beijing-aosaikang-pharmaceutical-co-ltd-class-a-szs-f01068bb4cb409d0Pharma Surgeen2026-07-22T05:45:10.000ZPrice to earnings forward of Beijing Aosaikang Pharmaceutical Co., Ltd. Class A – SZSE:002755https://www.pharmaradar360.com/article/u-s-biotech-ceo-explains-why-he-chose-hong-kong-for-primary-listing-39f8c09a675d49daPharma Surgeen2026-07-22T05:13:00.000ZU.S. biotech CEO explains why he chose Hong Kong for primary listinghttps://www.pharmaradar360.com/article/aribio-to-present-ar1001-phase-3-clinical-trial-results-at-ctad-in-november-7204320b26ab59c7Pharma Surgeen2026-07-22T05:12:00.000ZAribio to Present AR1001 Phase 3 Clinical Trial Results at CTAD in Novemberhttps://www.pharmaradar360.com/article/ing-podcast-examines-china-s-biotech-rise-and-shifting-global-pharma-order-9e8aa15348b19d64Pharma Surgeen2026-07-22T05:11:50.000ZING podcast examines China’s biotech rise and shifting global pharma orderhttps://www.pharmaradar360.com/article/thailand-courts-korean-investment-in-biotech-wellness-sectors-2f4b41ea1b95789bPharma Surgeen2026-07-22T04:52:32.000ZThailand courts Korean investment in biotech, wellness sectorshttps://www.pharmaradar360.com/article/lonza-raises-core-profit-margin-target-after-solid-first-half-10849dd4d5c6f246Pharma Surgeen2026-07-22T04:51:00.000ZLonza raises core profit margin target after solid first halfhttps://www.pharmaradar360.com/article/where-to-find-healthy-profits-in-biotech-bcb3792bc295d6d1Pharma Surgeen2026-07-22T04:00:00.000ZWhere to find healthy profits in biotechhttps://www.pharmaradar360.com/article/sex-offender-a-fugitive-for-21-years-hid-in-plain-sight-as-a-yacht-owning-l-a-bi-a16e2b45e4e87735Pharma Surgeen2026-07-22T03:43:00.000ZSex offender, a fugitive for 21 years, hid in plain sight as a yacht-owning L.A. biopharma exechttps://www.pharmaradar360.com/article/is-krystal-biotech-krys-overvalued-on-its-kb801-patent-data-update-ff981b788ad4fc4fPharma Surgeen2026-07-22T03:37:51.000ZIs Krystal Biotech (KRYS) Overvalued On Its KB801 Patent Data Update?https://www.pharmaradar360.com/article/the-ai-ebb-gives-way-to-biotech-as-winners-emerge-in-the-u-s-ipo-market-4fba6c2638aa343dPharma Surgeen2026-07-22T02:55:14.000ZThe AI Ebb Gives Way to Biotech as Winners Emerge in the U.S. IPO Markethttps://www.pharmaradar360.com/article/bio-asia-taiwan-2026-unites-60-countries-showcasing-taiwan-as-a-global-biotech-i-aef5b4d99c9246c0Pharma Surgeen2026-07-22T02:09:00.000ZBIO Asia-Taiwan 2026 Unites 60 Countries, Showcasing Taiwan as a Global Biotech Innovation Partnerhttps://www.pharmaradar360.com/article/trump-threatens-to-impose-tariffs-on-generic-drugs-666584971fb2e9e0Pharma Surgeen2026-07-22T01:24:53.000ZTrump Threatens to Impose Tariffs on Generic Drugshttps://www.pharmaradar360.com/article/msd-advances-korea-linked-eye-drug-starts-four-phase-3-trials-vs-eylea-chosunbiz-e916c5eae1d70710Pharma Surgeen2026-07-22T01:18:00.000ZMSD advances Korea-linked eye drug, starts four phase 3 trials vs Eylea - CHOSUNBIZhttps://www.pharmaradar360.com/article/trump-plans-generic-drug-tariffs-from-2028-with-two-year-delay-testing-u-s-onsho-d5e8b12ef9caf861Pharma Surgeen2026-07-22T01:17:00.000ZTrump plans generic drug tariffs from 2028 with two-year delay testing U.S. onshoring pushhttps://www.pharmaradar360.com/article/is-your-allergy-medicine-safe-fda-recalls-antihistamine-tablets-over-life-threat-103a9c835338e8bePharma Surgeen2026-07-22T00:57:11.000ZIs Your Allergy Medicine Safe? FDA Recalls Antihistamine Tablets Over Life-Threatening Contamination Concernshttps://www.pharmaradar360.com/article/shapiro-administration-launches-125m-fund-for-biotech-startups-3852c653f994f3f6Pharma Surgeen2026-07-22T00:55:49.000ZShapiro administration launches $125M fund for biotech startupshttps://www.pharmaradar360.com/article/trump-says-he-will-impose-tariffs-on-generic-drugs-starting-in-august-2028-d65d92ace69a623fPharma Surgeen2026-07-22T00:52:00.000ZTrump says he will impose tariffs on generic drugs starting in August 2028https://www.pharmaradar360.com/article/kolon-tissuegene-plunges-again-as-us-phase-3-for-arthritis-therapy-fails-chosunb-4218c157885dbd2dPharma Surgeen2026-07-22T00:50:00.000ZKolon TissueGene plunges again as US phase 3 for arthritis therapy fails - CHOSUNBIZhttps://www.pharmaradar360.com/article/aribio-to-present-ar1001-phase-3-results-at-ctad-2026-in-boston-ef828346a933baaePharma Surgeen2026-07-22T00:31:25.000ZAriBio to present AR1001 phase 3 results at CTAD 2026 in Bostonhttps://www.pharmaradar360.com/article/consolidated-hiv-guidelines-service-delivery-2795201105f2e9e4Pharma Surgeen2026-07-22T00:00:00.000ZConsolidated HIV guidelines: service deliveryhttps://www.pharmaradar360.com/article/sfda-grants-orphan-drug-designation-to-gritgen-therapeutics-for-pku-treatment-0f6ab801f6b87ab0Pharma Surgeen2026-07-22T00:00:00.000ZSFDA Grants Orphan Drug Designation to Gritgen Therapeutics for PKU Treatmenthttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-ff80dad4529023a8Pharma Surgeen2026-07-22T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-2b121d00efb8d795Pharma Surgeen2026-07-22T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-olaparib-tablets-from-the-united-states-fo-601ca10e2cc85c2bPharma Surgeen2026-07-22T00:00:00.000Znatco receives tentative approval for olaparib tablets from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-e1e7b14095cbfee3Pharma Surgeen2026-07-22T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-5331b1594f6ef544Pharma Surgeen2026-07-22T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-409698ebf7a054bcPharma Surgeen2026-07-22T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-d25286b7ae5dea4aPharma Surgeen2026-07-22T00:00:00.000Znatco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limitedhttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-90b1813202160774Pharma Surgeen2026-07-22T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-c36d9feae1adef2aPharma Surgeen2026-07-22T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-41d29e58c5900668Pharma Surgeen2026-07-22T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-8e5ce6af3b749747Pharma Surgeen2026-07-22T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-81c3eb42cd4011a2Pharma Surgeen2026-07-22T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-421cdfd06160e1e8Pharma Surgeen2026-07-22T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/home-page-5ed03e84f5e7c483Pharma Surgeen2026-07-22T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/view-latest-results-ec5f7049f7dae5acPharma Surgeen2026-07-22T00:00:00.000ZView latest resultshttps://www.pharmaradar360.com/article/submission-for-office-of-management-and-budget-review-generic-for-administration-e37562db68cd460dPharma Surgeen2026-07-22T00:00:00.000ZSubmission for Office of Management and Budget Review; Generic for Administration for Children and Families Program Monitoring Activitieshttps://www.pharmaradar360.com/article/determination-that-rasuvo-methotrexate-solution-27-5-milligrams-0-55-milliliter-5ac808971db7c933Pharma Surgeen2026-07-22T00:00:00.000ZDetermination That RASUVO (Methotrexate) Solution, 27.5 Milligrams/0.55 Milliliter (27.5 Milligrams/0.55 Milliliter), Was Not Withdrawn From Sale for Reasons of Safety or Effectivenesshttps://www.pharmaradar360.com/article/center-for-scientific-review-notice-of-closed-meetings-fd81174b1386a311Pharma Surgeen2026-07-22T00:00:00.000ZCenter for Scientific Review; Notice of Closed Meetingshttps://www.pharmaradar360.com/article/agency-information-collection-activities-submission-for-office-of-management-and-ce3e4f8d6652e063Pharma Surgeen2026-07-22T00:00:00.000ZAgency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Premarket Notifications Submissionhttps://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-public-comment-requ-a140cd12eef246faPharma Surgeen2026-07-22T00:00:00.000ZAgency Information Collection Activities: Proposed Collection: Public Comment Request; Information Collection Request Title: Advanced Nursing Education Program Specific Form OMB No. 0906-0089-Revisionhttps://www.pharmaradar360.com/article/bulk-manufacturer-of-controlled-substances-application-cerilliant-corporation-c3ddeba7d306409fPharma Surgeen2026-07-22T00:00:00.000ZBulk Manufacturer of Controlled Substances Application: Cerilliant Corporationhttps://www.pharmaradar360.com/article/nsg-bio-accelerates-breakthrough-biotech-innovation-in-singapore-75992e25bf7ad0a5Pharma Surgeen2026-07-22T00:00:00.000ZNSG Bio Accelerates Breakthrough Biotech Innovation in Singaporehttps://www.pharmaradar360.com/article/united-therapeutics-corporation-to-report-second-quarter-2026-financial-results-9045d645d5be4c52Pharma Surgeen2026-07-22T00:00:00.000ZUnited Therapeutics Corporation to Report Second Quarter 2026 Financial Results Before Market Open on Wednesday, August 5, 2026https://www.pharmaradar360.com/article/perrigo-to-release-second-quarter-2026-financial-results-on-august-5-2026-a97830a208ca502dPharma Surgeen2026-07-22T00:00:00.000ZPerrigo to Release Second Quarter 2026 Financial Results on August 5, 2026https://www.pharmaradar360.com/article/mechanisms-regulating-combination-effect-of-antibody-drug-conjugates-and-cancer-e6c48943c9a115b2Pharma Surgeen2026-07-22T00:00:00.000ZMechanisms regulating combination effect of antibody-drug conjugates and cancer immunotherapyhttps://www.pharmaradar360.com/article/statistical-integration-of-gwas-eqtl-and-pqtl-data-for-multi-omics-analysis-of-a-0968cbd76144850aPharma Surgeen2026-07-22T00:00:00.000ZStatistical integration of GWAS, eQTL and pQTL data for multi-omics analysis of Alzheimer's Diseasehttps://www.pharmaradar360.com/article/kras-g12c-targeted-therapy-strategy-for-lung-cancer-mechanism-clinical-practice-96344c0257245e39Pharma Surgeen2026-07-22T00:00:00.000ZKRAS G12C-Targeted Therapy Strategy for Lung Cancer: Mechanism, Clinical Practice and Challengeshttps://www.pharmaradar360.com/article/clinical-outcomes-of-arthroscopic-stabilization-procedures-in-patients-with-shou-89aa9f858bbf2d83Pharma Surgeen2026-07-22T00:00:00.000ZClinical outcomes of arthroscopic stabilization procedures in patients with shoulder dislocation combined with posttraumatic adhesive capsulitishttps://www.pharmaradar360.com/article/clinical-and-diagnostic-significance-of-vascular-and-metabolic-factors-in-the-de-d04db77dc59fc72dPharma Surgeen2026-07-22T00:00:00.000ZClinical and Diagnostic Significance of Vascular and Metabolic Factors in the Development of Cognitive Impairment in Patients with Chronic Somatic Diseaseshttps://www.pharmaradar360.com/article/seeking-1da694cfb763d58dPharma Surgeen2026-07-22T00:00:00.000ZSeekinghttps://www.pharmaradar360.com/article/off-label-use-of-teriparatide-for-osteotomy-healing-in-an-adolescent-with-osteog-60892235869834dfPharma Surgeen2026-07-22T00:00:00.000ZOff-Label Use of Teriparatide for Osteotomy Healing in an Adolescent with Osteogenesis Imperfecta Type VIII: A Case Reporthttps://www.pharmaradar360.com/article/prolactinoma-associated-with-l-dopa-resistant-hyperprolactinemia-in-a-child-with-bc4d4db35afc9b00Pharma Surgeen2026-07-22T00:00:00.000ZProlactinoma Associated with L-Dopa–Resistant Hyperprolactinemia in a Child with Tetrahydropterin (BH4) Deficiencyhttps://www.pharmaradar360.com/article/real-world-risk-assessment-of-drug-induced-cytokine-release-syndrome-analysis-of-14ca5e9fe63fa860Pharma Surgeen2026-07-22T00:00:00.000ZReal-world risk assessment of drug-induced cytokine release syndrome: Analysis of the Food and Drug Administration Adverse Event Reporting Systemhttps://www.pharmaradar360.com/article/enhancing-oral-bioavailability-of-poorly-water-soluble-natural-products-via-lipi-4228af30955601b4Pharma Surgeen2026-07-22T00:00:00.000ZEnhancing Oral Bioavailability of Poorly Water-Soluble Natural Products via Lipid–Drug Conjugateshttps://www.pharmaradar360.com/article/from-susceptibility-to-disease-severity-re-discovering-the-clinical-role-of-mmp-b98770429d3d0395Pharma Surgeen2026-07-22T00:00:00.000ZFrom Susceptibility to Disease Severity: Re-Discovering the Clinical Role of MMP-12 Genotypes in Asthmahttps://www.pharmaradar360.com/article/hypochloremia-in-older-adults-with-heart-failure-from-pathophysiology-to-prognos-7a418b291e03f797Pharma Surgeen2026-07-22T00:00:00.000ZHypochloremia in Older Adults with Heart Failure: From Pathophysiology to Prognosishttps://www.pharmaradar360.com/article/beyond-the-four-pillars-a-risk-targeted-framework-for-vericiguat-a-narrative-rev-2c9d596292391407Pharma Surgeen2026-07-22T00:00:00.000ZBeyond the Four Pillars: A Risk-Targeted Framework for Vericiguat—A Narrative Reviewhttps://www.pharmaradar360.com/article/association-of-serial-intra-abdominal-pressure-measurements-with-renal-outcomes-1213debd9e01e8f9Pharma Surgeen2026-07-22T00:00:00.000ZAssociation of Serial Intra-Abdominal Pressure Measurements with Renal Outcomes and Mortality in Critically Ill Adultshttps://www.pharmaradar360.com/article/hypofractionated-versus-conventional-postmastectomy-radiotherapy-in-implant-base-1caa43ef2310d0b7Pharma Surgeen2026-07-22T00:00:00.000ZHypofractionated Versus Conventional Postmastectomy Radiotherapy in Implant-Based Breast Reconstruction: A Systematic Review and Meta-Analysishttps://www.pharmaradar360.com/article/association-between-metabolic-obesity-phenotypes-and-alcohol-associated-fatty-li-c3a28c2679ffecc8Pharma Surgeen2026-07-22T00:00:00.000ZAssociation Between Metabolic Obesity Phenotypes and Alcohol-Associated Fatty Liver Disease Among US Adults: A NHANES 2013–2018 Analysishttps://www.pharmaradar360.com/article/the-cally-index-in-critical-illness-risk-stratification-and-its-potential-role-i-2435e6a0331bd635Pharma Surgeen2026-07-22T00:00:00.000ZThe CALLY Index in Critical Illness: Risk Stratification and Its Potential Role in Clinical Monitoringhttps://www.pharmaradar360.com/article/integrative-network-pharmacology-and-admet-modeling-reveal-the-multitarget-thera-1b994155d8e044b6Pharma Surgeen2026-07-22T00:00:00.000ZIntegrative Network Pharmacology and ADMET Modeling Reveal the Multitarget Therapeutic Potential of Geraniolhttps://www.pharmaradar360.com/article/apert-syndrome-oral-maxillofacial-and-dental-management-a-narrative-clinical-rev-bdf4d39ca3f676aePharma Surgeen2026-07-22T00:00:00.000ZApert Syndrome: Oral, Maxillofacial and Dental Management—A Narrative Clinical Reviewhttps://www.pharmaradar360.com/article/retracted-kshirsagar-et-al-a-combination-therapy-of-urolithin-a-egcg-has-stronge-bd3d023a8ad0ee8bPharma Surgeen2026-07-22T00:00:00.000ZRETRACTED: Kshirsagar et al. A Combination Therapy of Urolithin A+EGCG Has Stronger Protective Effects than Single Drug Urolithin A in a Humanized Amyloid Beta Knockin Mice for Late-Onset Alzheimer’s Disease. Cells 2022, 11, 2660https://www.pharmaradar360.com/article/cancer-associated-fibroblast-heterogeneity-and-extracellular-matrix-remodeling-a-51770aa11e094735Pharma Surgeen2026-07-22T00:00:00.000ZCancer-Associated Fibroblast Heterogeneity and Extracellular Matrix Remodeling as Orchestrators of Drug Resistance in Upper Gastrointestinal Cancers: Insights from Spatial Multi-Omics and Therapeutic Implicationshttps://www.pharmaradar360.com/article/comparative-analysis-of-methicillin-susceptible-staphylococcus-aureus-and-strept-da4c7e3d90ec56dcPharma Surgeen2026-07-22T00:00:00.000ZComparative Analysis of Methicillin-Susceptible Staphylococcus aureus and Streptococcal Native Joint Septic Arthritis: Clinical Characteristics and Outcomeshttps://www.pharmaradar360.com/article/clinical-equipoise-and-ethical-challenges-in-expanding-endovascular-stroke-throm-b95e06e9a95f696bPharma Surgeen2026-07-22T00:00:00.000ZClinical equipoise and ethical challenges in expanding endovascular stroke thrombectomy practicehttps://www.pharmaradar360.com/article/intrapelvic-migration-of-a-trial-femoral-head-during-direct-anterior-approach-to-8c298d8f4d08d1a5Pharma Surgeen2026-07-22T00:00:00.000ZIntrapelvic migration of a trial femoral head during direct anterior approach total hip arthroplasty: a case report and literature reviewhttps://www.pharmaradar360.com/article/analysis-of-factors-influencing-post-pandemic-sleep-quality-among-hospital-clini-6e43f9654e80a8ddPharma Surgeen2026-07-22T00:00:00.000ZAnalysis of factors influencing post-pandemic sleep quality among hospital clinical staff in Haikou, Chinahttps://www.pharmaradar360.com/article/implications-of-isonicotinylation-associated-patterns-in-nk-cells-in-the-pathoge-49677c34a724bf00Pharma Surgeen2026-07-22T00:00:00.000ZImplications of isonicotinylation-associated patterns in NK cells in the pathogenesis of Kawasaki disease: evidence from artificial intelligence-driven multi-omics and clinical validationhttps://www.pharmaradar360.com/article/a-6-week-ketogenic-diet-in-treatment-resistant-depression-a-prospective-single-a-9d813c0230bd0690Pharma Surgeen2026-07-22T00:00:00.000ZA 6-week ketogenic diet in treatment-resistant depression: a prospective single-arm feasibility pilot trialhttps://www.pharmaradar360.com/article/safety-of-transcutaneous-electrical-stimulation-potentiating-recovery-in-acute-s-f679227ca0250fafPharma Surgeen2026-07-22T00:00:00.000ZSafety of transcutaneous electrical stimulation potentiating recovery in acute spinal cord injury syndromes: a trial protocolhttps://www.pharmaradar360.com/article/efficacy-of-acupuncture-for-patients-with-parkinson-s-disease-related-constipati-fd6e4404d30672efPharma Surgeen2026-07-22T00:00:00.000ZEfficacy of acupuncture for patients with Parkinson’s disease–related constipation: study protocol for a randomized controlled, double-blind trialhttps://www.pharmaradar360.com/article/the-role-of-otud1-mediated-deubiquitination-in-disease-pathogenesis-from-molecul-e8b57327a04b589aPharma Surgeen2026-07-22T00:00:00.000ZThe role of OTUD1-mediated deubiquitination in disease pathogenesis: from molecular mechanisms to clinical translationhttps://www.pharmaradar360.com/article/efficacy-and-safety-of-mesenchymal-stem-cell-transplantation-for-progressive-mul-5a24a2a89e09a613Pharma Surgeen2026-07-22T00:00:00.000ZEfficacy and safety of mesenchymal stem cell transplantation for progressive multiple sclerosis: a systematic review and meta-analysis of randomized controlled trials with clinical implications for patient stratification and treatment optimizationhttps://www.pharmaradar360.com/article/a-mini-review-of-genome-predicted-lactam-susceptibility-in-streptococcus-pneumon-7bb891af7d4db5fePharma Surgeen2026-07-22T00:00:00.000ZA mini review of genome-predicted β-lactam susceptibility in Streptococcus pneumoniae: from PBP profiles to potential clinical interpretationhttps://www.pharmaradar360.com/article/ferroptosis-in-liver-diseases-molecular-mechanisms-biomarker-potential-and-clini-74c8050c30588e26Pharma Surgeen2026-07-22T00:00:00.000ZFerroptosis in liver diseases: molecular mechanisms, biomarker potential, and clinical translationhttps://www.pharmaradar360.com/article/potencial-risks-of-outbreaks-of-various-clinical-forms-of-enteroviral-infection-4bbbabb2daa79247Pharma Surgeen2026-07-22T00:00:00.000ZPotencial risks of outbreaks of various clinical forms of enteroviral infectionhttps://www.pharmaradar360.com/article/on-the-distance-eccentricity-indices-of-thorn-graphs-qspr-and-dft-applications-t-19033bfbefcabd57Pharma Surgeen2026-07-22T00:00:00.000ZOn the distance eccentricity indices of thorn graphs: QSPR and DFT applications to ocular drug design and molecular property predictionhttps://www.pharmaradar360.com/article/special-pre-trial-investigation-in-absentia-in-the-criminal-process-of-ukraine-e-8d84bb84f4277412Pharma Surgeen2026-07-22T00:00:00.000ZSpecial pre-trial investigation (in absentia) in the criminal process of Ukraine: evidentiary nature of grounds, subject of proof and judicial controlhttps://www.pharmaradar360.com/article/snapc4-related-neurodevelopmental-disorder-defines-a-stage-dependent-spliceosomo-f441b5df345e80d6Pharma Surgeen2026-07-22T00:00:00.000ZSNAPC4-related neurodevelopmental disorder defines a stage-dependent spliceosomopathy with heterogeneous clinical trajectorieshttps://www.pharmaradar360.com/article/the-medical-contour-as-a-proxy-indicator-of-adaptability-limits-of-clinical-comp-7baabedcb22b00dfPharma Surgeen2026-07-22T00:00:00.000ZThe medical contour as a proxy indicator of adaptability: limits of clinical compensation in a regional anti-drug system.https://www.pharmaradar360.com/article/pathological-fractures-in-rare-bone-diseases-clinical-cases-5a2a7d40798e097ePharma Surgeen2026-07-22T00:00:00.000ZPathological Fractures in Rare Bone Diseases: Clinical Caseshttps://www.pharmaradar360.com/article/smart-magnetic-carrier-for-controlled-anticancer-drug-delivery-synthesis-charact-6fbbc4293bd2a339Pharma Surgeen2026-07-22T00:00:00.000ZSmart magnetic carrier for controlled anticancer drug delivery: synthesis, characterization, and doxorubicin releasehttps://www.pharmaradar360.com/article/from-hospital-care-to-home-bringing-laboratory-led-poct-to-home-care-for-sodium-a49549bef837d294Pharma Surgeen2026-07-22T00:00:00.000ZFrom hospital care to home: bringing laboratory-led POCT to home care for sodium monitoring in pediatric patients with craniopharyngiomahttps://www.pharmaradar360.com/article/early-recognition-and-safe-management-of-unintentional-intrathecal-placement-of-f422f80448b0dc3fPharma Surgeen2026-07-22T00:00:00.000ZEarly recognition and safe management of unintentional intrathecal placement of an epidural catheter during combined spinal-epidural labor analgesia: a case report in the context of the 2024 OAA guidelineshttps://www.pharmaradar360.com/article/temporal-synchrony-promotes-motor-recovery-and-ipsilesional-cortical-reorganizat-d6e2d1364ed9aaf2Pharma Surgeen2026-07-22T00:00:00.000ZTemporal synchrony promotes motor recovery and ipsilesional cortical reorganization in BCI-based stroke rehabilitation: a randomized controlled trialhttps://www.pharmaradar360.com/article/the-association-between-nurses-personality-types-and-attitudes-towards-older-pat-f56521b61dcf4992Pharma Surgeen2026-07-22T00:00:00.000ZThe association between nurses’ personality types and attitudes towards older patients and their clinical decision-making styleshttps://www.pharmaradar360.com/article/do-video-animations-and-3-d-skull-models-reduce-preoperative-anxiety-in-bimaxill-984b8be63703f2f6Pharma Surgeen2026-07-22T00:00:00.000ZDo video animations and 3-D skull models reduce preoperative anxiety in bimaxillary orthognathic surgery patients? Randomized controlled trialhttps://www.pharmaradar360.com/article/patient-and-implant-level-factors-associated-with-peri-implant-diseases-a-retros-eb63ca43dc440ae4Pharma Surgeen2026-07-22T00:00:00.000ZPatient- and implant-level factors associated with peri-implant diseases: a retrospective clinical and radiographic study of 968 implantshttps://www.pharmaradar360.com/article/efficacy-and-safety-of-trimodal-dexmethylphenidate-ctx-1301-in-children-and-adol-54484a1c728dc66bPharma Surgeen2026-07-22T00:00:00.000ZEfficacy and Safety of Trimodal Dexmethylphenidate (CTx-1301) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: Results From a Phase 3, Randomized, Double-Blind, Fixed-Dose, Placebo-Controlled Trialhttps://www.pharmaradar360.com/article/tenecteplase-efficacy-in-patients-with-distal-occlusions-secondary-analysis-of-t-0febfd24986800e0Pharma Surgeen2026-07-22T00:00:00.000ZTenecteplase Efficacy in Patients With Distal Occlusions: Secondary Analysis of the TASTE Randomized Clinical Trialhttps://www.pharmaradar360.com/article/fecal-microbiota-transplantation-based-treatment-protocol-for-chronic-insomnia-d-89a96eb6ad9cc0d7Pharma Surgeen2026-07-22T00:00:00.000ZFecal microbiota transplantation‐based treatment protocol for chronic insomnia disorder: A randomized, double‐blind, placebo‐controlled trialhttps://www.pharmaradar360.com/article/art-therapy-marketing-and-fundraising-cost-and-revenue-patterns-in-u-s-hospital-c22870bcfcfb1956Pharma Surgeen2026-07-22T00:00:00.000ZArt therapy, marketing and fundraising: cost and revenue patterns in U.S. hospital foundationshttps://www.pharmaradar360.com/article/clinical-and-radiological-features-of-primary-breast-sarcoma-a-14-year-retrospec-9e63879286e74a7bPharma Surgeen2026-07-22T00:00:00.000ZClinical and radiological features of primary breast sarcoma: a 14-year retrospective case series from a single institutionhttps://www.pharmaradar360.com/article/harnessing-the-potential-of-spider-silk-proteins-as-emerging-biomaterials-for-dr-d21c2018444bb8b8Pharma Surgeen2026-07-22T00:00:00.000ZHarnessing the potential of spider silk proteins as emerging biomaterials for drug delivery: classification, comparative evaluation and future perspectives.https://www.pharmaradar360.com/article/e-resources-relevant-to-machine-learning-tools-for-medicinal-chemistry-fc47554fb08f2851Pharma Surgeen2026-07-22T00:00:00.000Ze-Resources Relevant to Machine Learning Tools for Medicinal Chemistryhttps://www.pharmaradar360.com/article/chemical-language-model-applications-in-medicinal-chemistry-bfe5577dd8e764caPharma Surgeen2026-07-22T00:00:00.000ZChemical Language Model Applications in Medicinal Chemistryhttps://www.pharmaradar360.com/article/machine-learning-in-drug-induced-adverse-reaction-modeling-case-studies-of-drug-e8d0ac0acec0f1c8Pharma Surgeen2026-07-22T00:00:00.000ZMachine Learning in Drug-induced Adverse Reaction Modeling: Case Studies of Drug-induced Cardiotoxicity Modelinghttps://www.pharmaradar360.com/article/machine-learning-in-drug-drug-interactions-28dfb21a4e30b3b2Pharma Surgeen2026-07-22T00:00:00.000ZMachine Learning in Drug–Drug Interactionshttps://www.pharmaradar360.com/article/machine-learning-in-predicting-the-physicochemical-properties-of-drug-candidates-484689d7e517f2eePharma Surgeen2026-07-22T00:00:00.000ZMachine Learning in Predicting the Physicochemical Properties of Drug Candidateshttps://www.pharmaradar360.com/article/exploratory-analyses-of-potential-moderators-of-a-personalized-intervention-to-r-d2cba4c390ee6d15Pharma Surgeen2026-07-22T00:00:00.000ZExploratory analyses of potential moderators of a personalized intervention to reduce preoperative anxiety: a secondary analysis of a randomized clinical trialhttps://www.pharmaradar360.com/article/mid-term-clinical-and-radiologic-outcomes-of-augmented-microfracture-with-decell-afe89e92219ea91ePharma Surgeen2026-07-22T00:00:00.000ZMid-term clinical and radiologic outcomes of augmented microfracture with decellularized particulated costal allocartilage for knee cartilage defects: four-year prospective case serieshttps://www.pharmaradar360.com/article/a-multimodal-vision-language-model-for-comprehensive-dental-diagnosis-and-enhanc-df68c6ecde54ce41Pharma Surgeen2026-07-22T00:00:00.000ZA multimodal vision-language model for comprehensive dental diagnosis and enhanced clinical practicehttps://www.pharmaradar360.com/article/optimizing-the-study-planning-phase-in-an-investigator-initiated-multicenter-cli-75cb79a73e7debcePharma Surgeen2026-07-22T00:00:00.000ZOptimizing the Study Planning Phase in an Investigator-Initiated Multicenter Clinical Trial: Mapping the Process into a Blueprinthttps://www.pharmaradar360.com/article/evaluation-of-the-anticancer-and-antibacterial-activities-of-several-new-drug-co-0ae17540ee54f69dPharma Surgeen2026-07-22T00:00:00.000ZEvaluation of the anticancer and antibacterial activities of several new drug conjugated systems based on mefenamic acidhttps://www.pharmaradar360.com/article/enterovirus-encephalitis-developing-after-treatment-for-follicular-lymphoma-a-ca-bb358164822b08afPharma Surgeen2026-07-22T00:00:00.000ZEnterovirus Encephalitis Developing After Treatment for Follicular Lymphoma: A Case Reporthttps://www.pharmaradar360.com/article/age-outweighs-route-for-aav-php-eb-transgene-distribution-via-inner-ear-delivery-c79694e60b9de907Pharma Surgeen2026-07-22T00:00:00.000ZAge outweighs route for AAV-PHP.eB transgene distribution via inner ear deliveryhttps://www.pharmaradar360.com/article/multiomics-and-artificial-intelligence-identify-infection-associated-subtypes-an-d65bcaa0672d40e6Pharma Surgeen2026-07-22T00:00:00.000ZMultiomics and artificial intelligence identify infection associated subtypes and prognostic signatures in hepatocellular carcinomahttps://www.pharmaradar360.com/article/unlocking-the-epigenetic-potential-of-ascorbic-acid-vitamin-c-in-cancer-therapy-51dc63cd19f0aac4Pharma Surgeen2026-07-22T00:00:00.000ZUnlocking the epigenetic potential of ascorbic acid (Vitamin C) in cancer therapyhttps://www.pharmaradar360.com/article/pneumocystis-jirovecii-pneumonia-and-prophylaxis-in-patients-with-solid-tumours-227376e2a8429381Pharma Surgeen2026-07-22T00:00:00.000ZPneumocystis jirovecii pneumonia and prophylaxis in patients with solid tumours: a narrative reviewhttps://www.pharmaradar360.com/article/nano-drug-delivery-of-a-new-scfv-based-immunotoxin-by-chitosan-nanoparticles-upg-e9dd515dfe06ca64Pharma Surgeen2026-07-22T00:00:00.000ZNano drug delivery of a new scfv-based immunotoxin by chitosan nanoparticles upgrades its efficiency against breast cancerhttps://www.pharmaradar360.com/article/early-termination-of-a-first-in-human-trial-of-a-swallowable-self-expanding-intr-9f8677b4aef5c64dPharma Surgeen2026-07-22T00:00:00.000ZEarly Termination of a First-in-Human Trial of a Swallowable Self-Expanding Intragastric Balloon (IGBalloon©) Due to Small Bowel Obstructionhttps://www.pharmaradar360.com/article/comparative-performance-of-chatgpt-and-gemini-in-diagnostic-classification-and-c-5632e52da034db5bPharma Surgeen2026-07-22T00:00:00.000ZComparative performance of chatgpt and gemini in diagnostic classification and clinical reasoning for open-angle glaucoma: a standardized scenario-based studyhttps://www.pharmaradar360.com/article/impact-of-updated-nccn-guidelines-on-clinical-management-and-risk-communication-b1ec4c39f2cf973ePharma Surgeen2026-07-22T00:00:00.000ZImpact of updated NCCN guidelines on clinical management and risk communication for CHEK2 p.I157T carriers in breast cancerhttps://www.pharmaradar360.com/article/clinical-professional-formation-among-social-work-students-professional-identity-a673dda22a6c13a7Pharma Surgeen2026-07-22T00:00:00.000ZClinical Professional Formation Among Social Work Students: Professional Identity, Clinical Self-Efficacy, Career Intention, and Commitmenthttps://www.pharmaradar360.com/article/systematic-review-of-extracellular-vesicle-based-liquid-biopsy-for-leptomeningea-074cc62d9d186d85Pharma Surgeen2026-07-22T00:00:00.000ZSystematic review of extracellular vesicle-based liquid biopsy for leptomeningeal metastasis: current evidence and future directionshttps://www.pharmaradar360.com/article/from-fatal-events-to-chronic-disability-the-evolving-clinical-landscape-of-pm2-5-9284ad1e1c5c8d1fPharma Surgeen2026-07-22T00:00:00.000ZFrom fatal events to chronic disability: The evolving clinical landscape of PM2.5-attributable hemorrhagic stroke in China (1990–2050)https://www.pharmaradar360.com/article/reticuline-alleviates-rheumatoid-arthritis-by-suppressing-the-jak-stat-signaling-c8a9f1643a76e82bPharma Surgeen2026-07-22T00:00:00.000ZReticuline alleviates rheumatoid arthritis by suppressing the JAK/STAT signaling pathwayhttps://www.pharmaradar360.com/article/clinical-characteristics-and-prognosis-of-primary-sjogren-s-disease-patients-wit-1d9ec104952f5a9cPharma Surgeen2026-07-22T00:00:00.000ZClinical characteristics and prognosis of primary Sjögren’s disease patients with hypocomplementemia: reduced C3 is independently associated with new-onset peripheral cytopeniashttps://www.pharmaradar360.com/article/predicting-the-risk-of-bone-erosion-in-rheumatoid-arthritis-using-a-shap-based-i-9dae500c8f082fb2Pharma Surgeen2026-07-22T00:00:00.000ZPredicting the risk of bone erosion in rheumatoid arthritis using a SHAP-based interpretable machine learning modelhttps://www.pharmaradar360.com/article/comparative-outcomes-of-aflibercept-8-mg-and-faricimab-in-neovascular-amd-refrac-1c946ecff7ec3c7aPharma Surgeen2026-07-22T00:00:00.000ZComparative outcomes of aflibercept 8 mg and faricimab in neovascular AMD refractory to aflibercept 2 mghttps://www.pharmaradar360.com/article/clinical-pharmacological-medication-reviews-for-insurants-of-a-german-statutory-21b8b9efaa65cc1bPharma Surgeen2026-07-22T00:00:00.000ZClinical-pharmacological medication reviews for insurants of a German statutory health insurance fund (Kaufmännische Krankenkasse (KKH)): a 5-year retrospective analysis (2019–2023)https://www.pharmaradar360.com/article/diphy-an-exploratory-tool-for-diurnal-physiology-and-tests-timing-in-clinical-pr-b92e09e5fbb4f7d8Pharma Surgeen2026-07-22T00:00:00.000ZDiPHY: An Exploratory Tool for Diurnal Physiology and Tests Timing in Clinical Practicehttps://www.pharmaradar360.com/article/early-onset-prostate-cancer-epidemiology-risk-factors-biology-clinical-features-727a071cd769d26cPharma Surgeen2026-07-22T00:00:00.000ZEarly‐Onset Prostate Cancer: Epidemiology, Risk Factors, Biology, Clinical Features, Management, and Early Detectionhttps://www.pharmaradar360.com/article/mechanical-thrombectomy-in-ischemic-stroke-with-a-medium-or-distal-arterial-occl-3cc3e8480dccf94fPharma Surgeen2026-07-22T00:00:00.000ZMechanical Thrombectomy in Ischemic Stroke With a Medium or Distal Arterial Occlusionhttps://www.pharmaradar360.com/article/nct07721090-improving-prescribing-quality-for-oral-mucosal-disorders-using-a-pha-e823cff9cde9bb54Pharma Surgeen2026-07-22T00:00:00.000ZNCT07721090: Improving Prescribing Quality for Oral Mucosal Disorders Using a Pharmacist-Led Modelhttps://www.pharmaradar360.com/article/nct07721051-the-effect-of-using-different-scaffolds-in-retreated-teeth-on-the-cl-1e04e77d1a859b27Pharma Surgeen2026-07-22T00:00:00.000ZNCT07721051: The Effect of Using Different Scaffolds in Retreated Teeth on The Clinical and Radiological Success of Regenerative Endodontic Treatmenthttps://www.pharmaradar360.com/article/nct07720830-identification-of-genetic-variants-associated-with-lichen-sclerosus-cd9472fd757ff72fPharma Surgeen2026-07-22T00:00:00.000ZNCT07720830: Identification of Genetic Variants Associated With Lichen Sclerosushttps://www.pharmaradar360.com/article/nct07720765-optical-coherence-tomography-in-neurological-practice-utility-and-ap-6528689f83662d05Pharma Surgeen2026-07-22T00:00:00.000ZNCT07720765: Optical Coherence Tomography in Neurological Practice: Utility and Applicability Across Neurological Diseases (OCt.IN.N)https://www.pharmaradar360.com/article/nct07720362-open-label-clinical-trial-evaluating-the-impact-of-a-multi-strain-co-97b8ccc4b9db71a2Pharma Surgeen2026-07-22T00:00:00.000ZNCT07720362: Open-Label Clinical Trial Evaluating the Impact of a Multi-Strain Commensal Probiotic Dietary Supplement on Gastrointestinal Microbiota Composition, Functional Gastrointestinal Markers, and Gastrointestinal Symptomshttps://www.pharmaradar360.com/article/nct07720076-effectiveness-of-breastfeeding-education-using-a-lactation-simulatio-d1f3c6324c15fd55Pharma Surgeen2026-07-22T00:00:00.000ZNCT07720076: Effectiveness of Breastfeeding Education Using a Lactation Simulation Model Among Nursing Students: A Randomized Controlled Trialhttps://www.pharmaradar360.com/article/nct07720063-group-treatment-for-self-harming-adolescents-and-their-parents-a-ran-e1b9e34929f5c2b3Pharma Surgeen2026-07-22T00:00:00.000ZNCT07720063: Group Treatment for Self-harming Adolescents and Their Parents: a Randomized Controlled Trialhttps://www.pharmaradar360.com/article/nct07719959-a-randomized-controlled-trial-of-3d-airway-reconstruction-for-precis-fa79bd59a9085dc5Pharma Surgeen2026-07-22T00:00:00.000ZNCT07719959: A Randomized Controlled Trial of 3D Airway Reconstruction for Precise Double-Lumen Bronchial Intubationhttps://www.pharmaradar360.com/article/nct07719790-does-erectile-dysfonction-allow-to-evaluate-subendocardial-viability-ef9ab552e90c2242Pharma Surgeen2026-07-22T00:00:00.000ZNCT07719790: Does Erectile Dysfonction Allow to Evaluate Subendocardial Viability Among Treated Patients With Hypertension ?https://www.pharmaradar360.com/article/nct07719504-implementation-of-physical-therapy-protocol-for-functional-constipat-c47539931e140688Pharma Surgeen2026-07-22T00:00:00.000ZNCT07719504: IMPLEMENTATION OF PHYSICAL THERAPY PROTOCOL FOR FUNCTIONAL CONSTIPATIONhttps://www.pharmaradar360.com/article/nct07719296-hiit-cardiorespiratory-fitness-and-metabolic-health-in-healthy-young-990afa99a906a08ePharma Surgeen2026-07-22T00:00:00.000ZNCT07719296: HIIT, Cardiorespiratory Fitness, and Metabolic Health in Healthy Young Adultshttps://www.pharmaradar360.com/article/nct07719257-evaluation-of-the-safety-tolerability-and-pharmacokinetics-of-tul108-9047429b7753a1e9Pharma Surgeen2026-07-22T00:00:00.000ZNCT07719257: Evaluation of the Safety, Tolerability and Pharmacokinetics of TUL108 for Injection in Healthy Participants (SAD/ MAD)https://www.pharmaradar360.com/article/nct07719088-psilocybin-effects-on-healthy-aging-biomarkers-and-purpose-in-life-1860d52bff635643Pharma Surgeen2026-07-22T00:00:00.000ZNCT07719088: Psilocybin Effects on Healthy Aging Biomarkers and Purpose in Lifehttps://www.pharmaradar360.com/article/nct07719062-ai-chatbot-for-prostate-radiation-therapy-patient-education-6553e73107d6eac1Pharma Surgeen2026-07-22T00:00:00.000ZNCT07719062: AI Chatbot for Prostate Radiation Therapy Patient Educationhttps://www.pharmaradar360.com/article/nct07718490-immunotheray-combined-with-simvastatin-and-target-therapy-and-chemot-20f00fc8f37a2502Pharma Surgeen2026-07-22T00:00:00.000ZNCT07718490: Immunotheray Combined With Simvastatin and Target Therapy and Chemotharepy for Advanced Colorectal Cancerhttps://www.pharmaradar360.com/article/nct07717710-ivabradine-for-heart-rate-reduction-during-exercise-in-healthy-adult-3c05dde6739b44c2Pharma Surgeen2026-07-22T00:00:00.000ZNCT07717710: Ivabradine for Heart Rate Reduction During Exercise in Healthy Adultshttps://www.pharmaradar360.com/article/nct07715396-addition-of-platinum-based-chemotherapy-to-tislelizumab-in-pd-l1high-5a880a8e305de9f7Pharma Surgeen2026-07-22T00:00:00.000ZNCT07715396: Addition of Platinum-based Chemotherapy to Tislelizumab in PD-L1high Metastatic Non-small Cell Lung Cancer With a High Tumor Burdenhttps://www.pharmaradar360.com/article/nct07711691-empowering-patients-lung-cancer-screening-uptake-empower-lcs-call-d695c3758c9956d9Pharma Surgeen2026-07-22T00:00:00.000ZNCT07711691: Empowering Patients' Lung Cancer Screening Uptake (Empower LCS/Call+)https://www.pharmaradar360.com/article/nct07702617-effects-of-vacuum-controlled-static-versus-vacuum-controlled-dynamic-4921e3bee2881847Pharma Surgeen2026-07-22T00:00:00.000ZNCT07702617: Effects Of Vacuum Controlled Static Versus Vacuum Controlled Dynamic Dry Cupping On Pain, Range Of Motion And Disability Among Patients With Chronic Low Back Painhttps://www.pharmaradar360.com/article/nct07684066-d-tect-pretreatment-d-dimers-and-disease-control-in-advanced-cscc-tr-1d6144684afa47a4Pharma Surgeen2026-07-22T00:00:00.000ZNCT07684066: D-TECT: Pretreatment D-dimers and Disease Control in Advanced cSCC Treated With Cemiplimabhttps://www.pharmaradar360.com/article/nct07648264-single-arm-study-of-igpro20-in-adults-with-secondary-immune-deficien-4a1e442133aef185Pharma Surgeen2026-07-22T00:00:00.000ZNCT07648264: Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapieshttps://www.pharmaradar360.com/article/nct07621640-brown-adipose-tissue-as-a-mechanistic-determinant-of-semaglutide-tre-6c002de9cc5c4bdePharma Surgeen2026-07-22T00:00:00.000ZNCT07621640: Brown Adipose Tissue as a Mechanistic Determinant of Semaglutide Treatment Response in Obesity (BAT-Sema Study)https://www.pharmaradar360.com/article/nct07619534-collection-of-csf-samples-from-participants-with-metastatic-triple-n-499b6b2cc3691899Pharma Surgeen2026-07-22T00:00:00.000ZNCT07619534: Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastaseshttps://www.pharmaradar360.com/article/nct07607678-a-study-in-people-with-advanced-cancer-to-test-how-well-different-do-e5ddc833a1155867Pharma Surgeen2026-07-22T00:00:00.000ZNCT07607678: A Study in People With Advanced Cancer to Test How Well Different Doses of BI 3819026 Are Tolerated When Taken Alone and Together With Ezabenlimabhttps://www.pharmaradar360.com/article/nct07574541-multitargeted-recombinant-ad5-psa-muc-1-brachyury-based-immunotherap-0f3af0b930fedd23Pharma Surgeen2026-07-22T00:00:00.000ZNCT07574541: Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillancehttps://www.pharmaradar360.com/article/nct07516379-graft-2-0-a-multimodal-prospective-approach-to-define-the-mechanisms-4b73c2f8366de2e5Pharma Surgeen2026-07-22T00:00:00.000ZNCT07516379: GRAfT 2.0. A Multimodal Prospective Approach to Define the Mechanisms and Clinical Features of Acute and Chronic Rejection in Lung Transplantationhttps://www.pharmaradar360.com/article/nct07430904-empowerment-program-to-reduce-treatment-of-asymptomatic-bacteriuria-f53f461173aa829cPharma Surgeen2026-07-22T00:00:00.000ZNCT07430904: Empowerment Program to Reduce Treatment of Asymptomatic Bacteriuria in Veterans With Spinal Cord Injuryhttps://www.pharmaradar360.com/article/nct07239947-a-study-of-bbt001-in-healthy-volunteers-hvs-and-in-adult-patients-wi-9ab9f0f4de7dc97aPharma Surgeen2026-07-22T00:00:00.000ZNCT07239947: A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Moderate to Severe Atopic Dermatitis (AD)https://www.pharmaradar360.com/article/nct07224425-a-study-of-bi-3810944-in-patients-with-advanced-cancer-40248b86784ee316Pharma Surgeen2026-07-22T00:00:00.000ZNCT07224425: A Study of BI 3810944 in Patients With Advanced Cancerhttps://www.pharmaradar360.com/article/nct07216456-vaginal-dilator-therapy-after-pelvic-radiation-4b4b2895b662bc84Pharma Surgeen2026-07-22T00:00:00.000ZNCT07216456: Vaginal Dilator Therapy After Pelvic Radiationhttps://www.pharmaradar360.com/article/nct07201896-trial-of-device-that-is-not-approved-or-cleared-by-the-u-s-fda-7c00a5f47cf7230fPharma Surgeen2026-07-22T00:00:00.000ZNCT07201896: [Trial of device that is not approved or cleared by the U.S. FDA]https://www.pharmaradar360.com/article/nct07194707-effect-of-operating-room-noise-on-bis-and-hemodynamics-under-general-955f3a7755620f20Pharma Surgeen2026-07-22T00:00:00.000ZNCT07194707: Effect of Operating Room Noise on BIS and Hemodynamics Under General Anesthesiahttps://www.pharmaradar360.com/article/nct07155174-a-study-to-evaluate-the-optimal-dose-adverse-events-and-change-in-di-615fd225a57f8a34Pharma Surgeen2026-07-22T00:00:00.000ZNCT07155174: A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancerhttps://www.pharmaradar360.com/article/nct07118215-a-study-to-evaluate-the-effects-of-karxt-on-the-drug-levels-of-midaz-b891c9b0249ed0f4Pharma Surgeen2026-07-22T00:00:00.000ZNCT07118215: A Study to Evaluate the Effects of KarXT on the Drug Levels of Midazolam, Fexofenadine, and Digoxinhttps://www.pharmaradar360.com/article/nct06758401-this-is-a-study-to-learn-about-how-the-combination-of-the-study-medi-4497c0c88d27fe1ePharma Surgeen2026-07-22T00:00:00.000ZNCT06758401: This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.https://www.pharmaradar360.com/article/nct06733649-treatment-education-for-perinatal-women-and-their-community-support-5ed4e9b2539759b6Pharma Surgeen2026-07-22T00:00:00.000ZNCT06733649: Treatment Education for Perinatal Women and Their Community Supporthttps://www.pharmaradar360.com/article/nct06615973-screening-for-social-determinants-of-health-sdoh-and-cognitive-funct-69af5e89852e6a1aPharma Surgeen2026-07-22T00:00:00.000ZNCT06615973: Screening for Social Determinants of Health (SDOH) and Cognitive Function in Individuals With History of Strokehttps://www.pharmaradar360.com/article/nct06595940-genetic-analysis-of-uncommon-disease-presentations-in-non-us-populat-9a7defcdd77feca2Pharma Surgeen2026-07-22T00:00:00.000ZNCT06595940: Genetic Analysis of Uncommon Disease Presentations in Non-US Populationshttps://www.pharmaradar360.com/article/nct06583577-ostomy-simulation-for-patient-education-prior-to-urologic-bowel-dive-ad459414b96d7935Pharma Surgeen2026-07-22T00:00:00.000ZNCT06583577: Ostomy Simulation for Patient Education Prior to Urologic Bowel Diversion Surgerieshttps://www.pharmaradar360.com/article/nct06502990-open-label-study-to-evaluate-metreleptin-in-children-under-6-years-o-cd34aeb01706731bPharma Surgeen2026-07-22T00:00:00.000ZNCT06502990: Open-label Study to Evaluate Metreleptin in Children Under 6 Years of Age With Generalised Lipodystrophyhttps://www.pharmaradar360.com/article/nct06498635-immunotherapy-after-surgery-for-people-who-have-no-remaining-cancer-11eb4c4e460ed51bPharma Surgeen2026-07-22T00:00:00.000ZNCT06498635: Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trialhttps://www.pharmaradar360.com/article/nct06471920-improving-health-for-patients-with-chronic-low-back-pain-in-rural-co-38a9abcfd78ba589Pharma Surgeen2026-07-22T00:00:00.000ZNCT06471920: Improving Health for Patients With Chronic Low Back Pain in Rural Communities Through Telerehabilitationhttps://www.pharmaradar360.com/article/nct06468618-developing-restful-environments-and-management-strategies-for-pediat-44e54a50243b8b6cPharma Surgeen2026-07-22T00:00:00.000ZNCT06468618: Developing Restful Environments and Management Strategies for Pediatric Stem Cell Transplant Patientshttps://www.pharmaradar360.com/article/nct06453213-open-label-study-of-cenobamate-monotherapy-in-adult-subjects-with-ne-26413ec02584ae9bPharma Surgeen2026-07-22T00:00:00.000ZNCT06453213: Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset Epilepsyhttps://www.pharmaradar360.com/article/nct06371417-phase-1b-trial-of-ray121-in-immunological-diseases-rainbow-trial-9cc8520ece967b80Pharma Surgeen2026-07-22T00:00:00.000ZNCT06371417: Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)https://www.pharmaradar360.com/article/nct06133387-paradigm-en-bloc-trial-with-the-endoquest-endoluminal-surgical-els-s-f7dcd8ba371962b9Pharma Surgeen2026-07-22T00:00:00.000ZNCT06133387: PARADIGM - En Bloc Trial With the EndoQuest Endoluminal Surgical (ELS) Systemhttps://www.pharmaradar360.com/article/nct06029270-testing-the-addition-of-bms-986016-relatlimab-to-the-usual-immunothe-c153aa9c2df6a533Pharma Surgeen2026-07-22T00:00:00.000ZNCT06029270: Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancerhttps://www.pharmaradar360.com/article/nct06013423-cord-blood-transplant-cyclophosphamide-fludarabine-and-total-body-ir-d87c546eb2153814Pharma Surgeen2026-07-22T00:00:00.000ZNCT06013423: Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseaseshttps://www.pharmaradar360.com/article/nct05879250-wp1066-and-radiation-therapy-in-treating-patients-with-newly-diagnos-e21be116dac74466Pharma Surgeen2026-07-22T00:00:00.000ZNCT05879250: WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastomahttps://www.pharmaradar360.com/article/nct05691478-a-study-to-test-the-addition-of-the-drug-cabozantinib-to-chemotherap-faed8be82b31b368Pharma Surgeen2026-07-22T00:00:00.000ZNCT05691478: A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcomahttps://www.pharmaradar360.com/article/nct05652478-early-metabolic-effects-of-antiretroviral-drugs-in-healthy-volunteer-3d00b83839f42b99Pharma Surgeen2026-07-22T00:00:00.000ZNCT05652478: Early Metabolic Effects of Antiretroviral Drugs in Healthy volUnteers: a Phase 2 Randomized Studyhttps://www.pharmaradar360.com/article/nct05506423-study-of-the-cyclopen-micro-interventional-system-and-long-term-clin-c84124d95790e79dPharma Surgeen2026-07-22T00:00:00.000ZNCT05506423: Study of the CycloPen Micro-Interventional System and Long-Term Clinical Outcomeshttps://www.pharmaradar360.com/article/nct05266417-intranasal-insulin-and-glutathione-as-an-add-on-therapy-in-parkinson-3679d7194d009ea4Pharma Surgeen2026-07-22T00:00:00.000ZNCT05266417: Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Diseasehttps://www.pharmaradar360.com/article/nct05142189-clinical-trial-evaluating-the-safety-tolerability-and-preliminary-ef-7e385b5824ac4e37Pharma Surgeen2026-07-22T00:00:00.000ZNCT05142189: Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancerhttps://www.pharmaradar360.com/article/nct04879329-a-study-of-disitamab-vedotin-alone-or-with-pembrolizumab-in-urotheli-0e8c1c49ebf003eePharma Surgeen2026-07-22T00:00:00.000ZNCT04879329: A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2https://www.pharmaradar360.com/article/nct04285086-ropeginterferon-alfa-2b-p1101-vs-anagrelide-in-essential-thrombocyth-6ca7e7c52bf0ffc8Pharma Surgeen2026-07-22T00:00:00.000ZNCT04285086: Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerancehttps://www.pharmaradar360.com/article/nct03866382-testing-the-effectiveness-of-two-immunotherapy-drugs-nivolumab-and-i-eefb8d105303abd2Pharma Surgeen2026-07-22T00:00:00.000ZNCT03866382: Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumorshttps://www.pharmaradar360.com/article/nct01059786-randomized-phase-ii-trial-of-rituximab-with-either-pentostatin-or-be-ff024bc85e044466Pharma Surgeen2026-07-22T00:00:00.000ZNCT01059786: Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemiahttps://www.pharmaradar360.com/article/nct01031160-health-behavior-in-school-age-children-next-longitudinal-study-2009-ce4e60684a0b7565Pharma Surgeen2026-07-22T00:00:00.000ZNCT01031160: Health Behavior in School-Age Children: NEXT Longitudinal Study 2009-2016https://www.pharmaradar360.com/article/nct00076310-osi-774-cisplatin-taxotere-in-head-neck-squamous-cell-cancer-2231d3601b674d6ePharma Surgeen2026-07-22T00:00:00.000ZNCT00076310: OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancerhttps://www.pharmaradar360.com/article/sputum-based-test-may-identify-drug-targets-in-asthma-and-copd-patient-care-onli-88a91a8a58f60cd3Pharma Surgeen2026-07-22T00:00:00.000ZSputum-Based Test May Identify Drug Targets in Asthma and COPD – Patient Care Onlinehttps://www.pharmaradar360.com/article/enliven-therapeutics-soaring-stock-faces-a-570-000-insider-reality-check-487a4173a6f7cfabPharma Surgeen2026-07-21T23:58:13.000ZEnliven Therapeutics' Soaring Stock Faces a $570,000 Insider Reality Checkhttps://www.pharmaradar360.com/article/wall-street-can-wait-why-one-u-s-biotech-firm-is-listing-in-hong-kong-first-5e20bf3c1d22bd91Pharma Surgeen2026-07-21T23:48:28.000ZWall Street can wait: Why one U.S. biotech firm is listing in Hong Kong firsthttps://www.pharmaradar360.com/article/trump-says-generic-drugs-to-face-no-us-tariffs-for-2-years-then-100-and-200-tari-25650132ef47f0bbPharma Surgeen2026-07-21T23:40:07.000ZTrump says generic drugs to face no US tariffs for 2 years, then 100% and 200% tariffs laterhttps://www.pharmaradar360.com/article/fervor-over-top-selling-drugs-fuels-biotech-dealmaking-15ccc1f1460edc2fPharma Surgeen2026-07-21T23:16:00.000ZFervor over top-selling drugs fuels biotech dealmakinghttps://www.pharmaradar360.com/article/cambium-bio-raises-aud-1-008-million-via-placement-to-fund-phase-3-elate-ocular-f3cdd2b0611c8323Pharma Surgeen2026-07-21T23:15:03.000ZCambium Bio Raises AUD 1.008 Million via Placement to Fund Phase 3 Elate Ocular Trialhttps://www.pharmaradar360.com/article/senate-panel-examines-china-s-influence-on-u-s-drug-supply-chain-819968738d8cdf88Pharma Surgeen2026-07-21T22:26:06.000ZSenate Panel Examines China's Influence on U.S. Drug Supply Chainhttps://www.pharmaradar360.com/article/news-divcowest-lands-biotech-headquarters-deal-at-revamped-boston-tower-0528d33fd0f112edPharma Surgeen2026-07-21T22:19:58.000ZNews | DivcoWest lands biotech headquarters deal at revamped Boston towerhttps://www.pharmaradar360.com/article/on-the-run-for-20-years-most-wanted-fugitive-caught-hiding-as-a-biotech-exec-957547f6c6bc554fPharma Surgeen2026-07-21T22:04:56.000ZOn the run for 20 years, most-wanted fugitive caught hiding as a biotech exec